Drugs / BXCL701 monotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03910660 | Feb 2019 → Oct 2023 | prostate cancer, small cell carcinoma | BioXcel Therapeutics Inc | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BXCL701 monotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03910660 ↗ |
| Action | Inhibit | “Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP 8/9)” PMID 42114950 ↗ May 2026 |
| Modality | Small molecule | “Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP 8/9)” PMID 42114950 ↗ May 2026 |
| Target | DPP4 | “Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP 8/9)” PMID 42114950 ↗ May 2026 |